FDA grants AP status for Methotrexate Sodium ANDA216453 by Elite Labs
The FDA has granted approval status (AP) for the Abbreviated New Drug Application ANDA216453 for Methotrexate Sodium submitted by Elite Labs.
Company
Pharmaceutical intelligence for Elite Labs with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.